Beth Hecht Sells 16,667 Shares of Xeris Biopharma (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Beth Hecht sold 16,667 shares of the company’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $7.43, for a total transaction of $123,835.81. Following the completion of the transaction, the insider owned 1,308,103 shares in the company, valued at $9,719,205.29. This trade represents a 1.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Beth Hecht also recently made the following trade(s):

• On Monday, December 1st, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The stock was sold at an average price of $7.01, for a total transaction of $116,835.67.
• On Tuesday, November 11th, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The shares were sold at an average price of $7.40, for a total transaction of $123,335.80.

Xeris Biopharma Stock Down 1.8%

Shares of NASDAQ:XERS opened at $6.96 on Wednesday. Xeris Biopharma Holdings, Inc. has a 12-month low of $3.14 and a 12-month high of $10.08. The company’s 50 day moving average price is $7.48 and its two-hundred day moving average price is $7.14. The firm has a market cap of $1.15 billion, a PE ratio of -69.59 and a beta of 0.50.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings results on Thursday, November 6th. The company reported $0.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.01). The company had revenue of $74.38 million during the quarter, compared to analyst estimates of $74.19 million. On average, research analysts expect that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current year.

Analyst Ratings Changes

XERS has been the subject of a number of analyst reports. Oppenheimer reaffirmed an “outperform” rating and issued a $18.00 price target on shares of Xeris Biopharma in a research note on Friday, November 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xeris Biopharma in a report on Wednesday, October 8th. Zacks Research downgraded shares of Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 30th. Wall Street Zen lowered shares of Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, Piper Sandler lifted their price objective on shares of Xeris Biopharma from $6.00 to $8.00 and gave the company a “neutral” rating in a research note on Friday, November 7th. Six research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Xeris Biopharma has a consensus rating of “Moderate Buy” and a consensus target price of $9.50.

Institutional Investors Weigh In On Xeris Biopharma

A number of hedge funds have recently made changes to their positions in XERS. AlphaQuest LLC acquired a new position in Xeris Biopharma during the 3rd quarter worth approximately $35,000. Northwestern Mutual Wealth Management Co. grew its stake in shares of Xeris Biopharma by 179.3% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock worth $63,000 after buying an additional 5,000 shares during the last quarter. State of Alaska Department of Revenue acquired a new position in shares of Xeris Biopharma during the third quarter worth $68,000. Mercer Global Advisors Inc. ADV bought a new position in shares of Xeris Biopharma in the 3rd quarter valued at $85,000. Finally, Brooklyn Investment Group acquired a new stake in shares of Xeris Biopharma during the 3rd quarter valued at $99,000. 42.75% of the stock is currently owned by institutional investors and hedge funds.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.